Bioavailability of Desmin, a low molecular weight dermatan sulfate, after subcutaneous administration to healthy volunteers

International Journal of Clinical and Laboratory Research

Volumn 27, Issue 2, 1997, Pages 195-198

  Miglioli, M ^a   Pironi, L ^a   Ruggeri, E ^a   Serra, C ^a   Zamboni, V ^b   Barbanti, M ^b   Canova, N ^b   Calanni, F ^b   Milani, M R ^b   Palazzini, E ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Alfa Wassermann SpA   (Italy)

Author keywords

Bioavailability; Coagulation; Desmin; Healthy volunteers; Low molecular weight dermatan sulfate

Indexed keywords

EID: 9844243442     PISSN: 09405437     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02912457     Document Type: Article

References (17)

1. Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258:6713.
2. Mascellani G, Bianchini P. European Patent 1990, no. 0221977. USA Patent no. 4973580.
3. Tamagnone G, Barbanti M. Desmin-370. Drugs Fut 1994; 19: 638.
4. Barbanti M, Calanni F, Babbini M, Bergonzini G, Parma B, Marchi E Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfate. Thromb Res 1993; 71:417.
5. Bergonzini GL, Bianchini P, Hoppensteadt Parma B, Osima B, Walenga JM, Fareed J. Pharmacokinetics of native and low molecular weight dermatan: preliminary results in rats and primates. Semin Thromb Hemost 1991; 17 (Suppl 2):235.
6. Barbanti M, Calanni F, Milani M, Marchi E, Semeraro N, Colucci M. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis - evidence for an anticoagulant-independent mechanism. Thromb Haemost 1993; 69: 147.
7. Barbanti M, Calanni F, Marchi E, Semeraro N, Colucci M. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in experimental venous thrombosis in rat: comparison with t-PA and u-PA (abstract). Thromb Haemost 1993; 69: 860.
8. Barbanti M, Calanni F, Marchi E, Semeraro N, Colucci M. Desmin 370, a low molecular weight dermatan sulphate reduces the weight of preformed thrombi in rats made afibrinogenemic by ancrod. Thromb Haemost 1995; 73:287.
9. Dettori AG, Galli G, Manotti C, Palazzim E. Pharmacological activity of a low molecular weight dermatan sulphate (Desmin) in healthy volunteers. Semin Thromb Hemost 1994; 20:259.
10. Legnani C, Palareti G, Biagi R, Ludovici S, Maggiore L, Milani M, Coccheri S. Acute and chronic clotting and fibrinolytic effect of a new low molecular weight dermatan sulphate (Desmin 370) in healthy subjects. Eur J Clin Pharmacol 1994; 47:247.
11. Dettori AG, Milani MR, Manotti C, Zamboni V, Palazzini E, Barbanti M. Pharmacology of Desmin (low molecular weight dermatan sulphate) in healthy volunteers following intravenous bolus administration of different dosages (200, 400, 800 mg). Thromb Res 1995; 79:249.
12. Cucinotta D, Manopulo R, Galati M, Zamboni V, Palazzini E, Barbanti M, Milani MR. Pharmacodynamics of a new low-molecular-weight dermatan sulfate after single subcutaneous injection in elderly patients with chronic venous disorders: a phase I trial. Curr Ther Res 1994; 55:1492.
13. Traini AM, Cervi V, Melandri G, Palazzini E, Zamboni V, Semprini F, Candiotti N, Branzi A. Pharmacodynamic characteristics of a low-molecular-weight dermatan sulphate after subcutaneous administration in acute myocardial infarction. J Int Med Res 1994; 22:323.
14. Huskisson EC. Measurement of pain. Lancet 1974; II:1127.
15. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 1990; 13:227.
16. Bara L, Mardiguian J, Samama M. In vitro effect on Heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities. Thromb Res 1990; 5:585.
17. Tripodi A, Moia M, Bottasso B, Tenconi PM, Gianese F, Mannucci PM. Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers. Thromb Res 1991; 62:663.